Last updated: August 1, 2026
Calcijex is an injectable formulation of calcitriol, the active vitamin D hormone used to manage hypocalcemia and secondary hyperparathyroidism in patients receiving chronic renal dialysis. Its commercial profile is weak for investment purposes: the product is an off-patent injectable, the brand has no meaningful exclusivity moat, generic calcitriol injection is available, and reimbursement is exposed to dialysis-provider purchasing and Medicare payment policies. The primary investment opportunity is not ownership of Calcijex itself but participation in low-cost generic manufacturing, sterile injectable capacity, or broader renal-care portfolios.
What is Calcijex and how does it work?
Calcijex is calcitriol injection, a sterile injectable vitamin D analog. Calcitriol is the hormonally active form of vitamin D and increases intestinal calcium absorption while influencing parathyroid hormone regulation.
The product was approved for use in patients undergoing chronic renal dialysis who have hypocalcemia and secondary hyperparathyroidism. The historical U.S. product was supplied as a 1 mcg/mL injection in single-dose ampules or vials, depending on the presentation and manufacturer labeling.[1]
Calcijex differs from oral vitamin D products because it provides active calcitriol without requiring renal conversion. The clinical market includes:
- Dialysis patients with secondary hyperparathyroidism
- Hospital and outpatient dialysis facilities
- Nephrology practices
- Institutional pharmacies
- Generic sterile-injectable suppliers
Calcitriol injection competes with oral calcitriol, paricalcitol, doxercalciferol and cinacalcet-based treatment strategies. The choice depends on calcium and phosphate levels, parathyroid hormone control, route of administration, formulary policy and dialysis-provider protocols.
What is the FDA status of Calcijex?
Calcijex was approved under U.S. New Drug Application No. 018874. The product’s regulatory history is associated with Abbott Laboratories, which historically marketed Calcijex in the United States.[2]
The branded product is no longer a significant commercial growth asset. FDA records identify Calcijex as a discontinued product, while calcitriol injection remains available through generic or alternative manufacturers in some markets.[2][3]
| Regulatory item |
Calcijex status |
| Active ingredient |
Calcitriol |
| Dosage form |
Intravenous injection |
| Historical strength |
1 mcg/mL |
| U.S. application |
NDA 018874 |
| Therapeutic area |
Nephrology, renal dialysis |
| FDA pathway |
Original NDA |
| Current brand-growth status |
No meaningful branded growth profile |
| Generic competition |
Established |
| Biosimilar relevance |
None |
| Regulatory sensitivity |
Sterility, potency, particulate matter and injectable manufacturing controls |
Calcijex is not a biologic. Biosimilar regulation does not apply. Competitive entry occurs through abbreviated new drug applications, manufacturing supplements, product transfers and facility approvals rather than through the biosimilar pathway.
When does Calcijex lose exclusivity?
Calcijex has already lost practical market exclusivity. The product is an older small-molecule injectable, and no commercially relevant branded exclusivity period remains.
The original patents associated with calcitriol and the historic Calcijex product have expired. The product’s investment case therefore depends on manufacturing economics, supply reliability and channel access rather than patent protection.
| Exclusivity category |
Current position |
| Compound patent |
Expired |
| Original product patent |
Expired or no longer commercially relevant |
| New chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial significance |
| Orphan exclusivity |
Not applicable |
| Formulation exclusivity |
No active commercial moat identified |
| Method-of-use exclusivity |
No current barrier to routine generic use |
| Patent-term extension |
No active extension relevant to commercial entry |
The absence of meaningful exclusivity means that a manufacturer cannot rely on premium pricing solely because it supplies calcitriol injection. Any pricing advantage must come from a shortage, limited approved supply, quality differentiation, contracting position or lower cost of goods.
What patents protect Calcijex?
No active Orange Book patent estate provides a material barrier to generic calcitriol injection in the United States. The product’s historic patent protection is expired, and current competition is driven by abbreviated regulatory approval and sterile-manufacturing capacity.
The relevant intellectual-property categories are:
Active-ingredient patents
Calcitriol is a mature molecule. Original compound protection expired long ago. A new entrant does not face an active composition-of-matter patent blocking routine generic development.
Formulation patents
Calcitriol injection requires formulation and container-closure controls because the product is a low-dose sterile injectable. Those technical requirements can create development and manufacturing complexity, but they do not constitute a durable patent barrier unless supported by an active, enforceable formulation patent.
No material active formulation patent is associated with Calcijex as a commercial asset.
Method-of-use patents
Calcitriol’s renal-dialysis indications are mature. No current method-of-use patent is known to create a meaningful restriction on generic use in the approved indications.
Manufacturing know-how
The practical barrier is process execution. A manufacturer must validate:
- Sterile filling and aseptic processing
- Low-dose content uniformity
- Stability through shelf life
- Container-closure integrity
- Control of particulates and endotoxins
- Compatibility with intravenous administration
- Quality-system compliance at the manufacturing site
This is operational know-how, not a Calcijex patent moat. Competitors can reproduce the required processes through independent development and regulatory filing.
How many patents cover Calcijex?
The commercially relevant number is zero active Orange Book patents that block generic calcitriol injection. Historical patents may appear in legacy records or broader calcitriol searches, but they do not create current branded exclusivity.
Patent-count analysis should distinguish between:
| Patent category |
Investment relevance |
| Expired calcitriol patents |
Historical only |
| Patents on unrelated vitamin D analogs |
Not applicable to Calcijex |
| Manufacturing patents held by suppliers |
Potentially relevant only to a specific process |
| Device or packaging patents |
Limited relevance for standard injection products |
| Active Orange Book patents |
No material barrier identified |
A high patent count in a broad calcitriol search would not indicate protection for Calcijex. The relevant question is whether an unexpired patent is listed against the approved product and enforceable against an ANDA applicant. The answer is no for the mature Calcijex product profile.
What is the Orange Book status of Calcijex?
The Orange Book records drug-product approvals and patent and exclusivity information, but a discontinued branded product does not create an ongoing commercial monopoly. Calcijex’s historical NDA does not support a current branded investment thesis.
The Orange Book analysis indicates:
- Calcijex is associated with a legacy NDA.
- The product does not have current new-drug exclusivity.
- No material active patent listing blocks generic entry.
- Generic applicants can compete through the ANDA pathway if they satisfy FDA requirements.
- Discontinuation of the brand does not eliminate the market for the active ingredient.
Generic availability can vary by presentation, manufacturer and time. A product may be approved but not consistently supplied. That distinction matters in sterile injectables, where manufacturing interruptions can produce temporary pricing power without creating durable protection.
Which companies are challenging Calcijex?
Calcijex does not face a conventional patent challenge because its patent estate is no longer commercially protective. Generic manufacturers compete through abbreviated approvals rather than Paragraph IV litigation.
The competitive set includes suppliers of calcitriol injection and competing renal therapies. Depending on market period and facility availability, competition may include generic injectable manufacturers such as Hikma, Fresenius Kabi, Sagent or other FDA-approved suppliers. Product availability and current manufacturer status must be assessed through FDA product databases and wholesale-channel records before assigning market share.
Are there Paragraph IV challenges to Calcijex?
No strategically important Paragraph IV campaign is associated with Calcijex. Paragraph IV litigation is generally relevant when a generic applicant challenges an unexpired listed patent. Calcijex lacks a material current patent barrier, so litigation is not the principal entry mechanism.
What generic entry risks exist for Calcijex?
Generic entry risk is already realized rather than prospective. The key commercial risks are price erosion and substitution.
Price erosion
Multiple suppliers can compete for dialysis and hospital contracts. Buyers typically favor products with reliable supply, acceptable quality history and competitive net pricing. A generic supplier without a cost or supply advantage can lose share rapidly.
Channel concentration
Dialysis providers and group purchasing organizations can exert substantial purchasing power. A supplier that depends on a small number of large contracts faces volume volatility when contracts are rebid.
Sterile-injectable disruption
Manufacturing problems can create temporary supply shortages. These events may support short-term price increases, but they also invite accelerated competition, regulatory scrutiny and customer switching.
Therapeutic substitution
Calcitriol injection competes with paricalcitol, doxercalciferol, oral calcitriol and cinacalcet. Dialysis protocols can shift toward products with different calcium or phosphate effects, limiting the ability of a calcitriol supplier to raise prices.
How does Calcijex compare with competing renal therapies?
| Product |
Active ingredient |
Route |
Main competitive attribute |
Patent position |
| Calcijex |
Calcitriol |
Injection |
Active vitamin D replacement in dialysis |
Mature, off-patent |
| Generic calcitriol |
Calcitriol |
Oral or injectable |
Lower-cost substitution |
Off-patent |
| Zemplar |
Paricalcitol |
Injection or oral |
Vitamin D analog with different clinical profile |
Original protection expired; generic competition |
| Hectorol |
Doxercalciferol |
Oral or injectable |
Alternative vitamin D analog |
Mature product; generic exposure |
| Sensipar and generics |
Cinacalcet |
Oral |
Calcimimetic mechanism |
Generic competition after patent expiry |
| Parsabiv |
Etelcalcetide |
Intravenous |
Dialysis-administered calcimimetic |
More recent product, but exposed to commercial and regulatory competition |
Calcijex has a low-cost and familiar active ingredient, but its differentiation is limited. Its strongest commercial use case is where clinicians require injectable calcitriol and the supplier has dependable delivery.
What is the revenue exposure for Calcijex?
Standalone Calcijex revenue is not a meaningful public-company reporting category. Historical brand sales were embedded in larger pharmaceutical portfolios, and current generic sales are typically reported within broader injectable or hospital-product segments.
Revenue exposure should be modeled through:
- Annual unit volume
- Average selling price per vial or ampule
- Contracted dialysis volume
- Generic supplier count
- Backorder frequency
- Cost of goods and manufacturing utilization
- Reimbursement changes affecting dialysis providers
A simple generic injectable revenue model is:
Revenue = annual units x net price per unit
Gross profit then depends on sterile manufacturing cost, fill-finish utilization, quality-control expense, distribution fees, rebates and contract discounts. A supply shortage can raise net price, but shortage-driven revenue should not be treated as recurring growth.
For an acquirer, Calcijex would be more valuable as part of a portfolio that shares:
- Injectable manufacturing capacity
- Dialysis-provider contracts
- Hospital distribution
- Regulatory personnel
- Pharmacovigilance and quality infrastructure
The product alone has limited strategic value unless it fills unused sterile capacity or improves a broader renal-care offering.
How strong is the patent estate for Calcijex?
The patent estate is weak. Its principal characteristics are:
| Patent-strength factor |
Assessment |
| Composition-of-matter protection |
None remaining |
| Orange Book exclusivity |
None of commercial significance |
| Formulation differentiation |
Limited |
| Method-of-use protection |
No material current barrier |
| Generic litigation leverage |
Low |
| Manufacturing complexity |
Moderate |
| Switching costs |
Low to moderate |
| Commercial moat |
Supply reliability and contracts |
The product has operational defensibility but no meaningful intellectual-property defensibility. That distinction is central to valuation.
What patent litigation and settlement agreements affect Calcijex?
No material current patent litigation or settlement agreement defines the Calcijex market. The product is too mature for a branded-generic settlement structure to drive market timing.
Potential disputes would more likely involve:
- ANDA approval or manufacturing compliance
- Product quality
- Trademark or trade-name use
- Contracting and supply obligations
- Product liability
- Regulatory status of a specific generic application
These issues can affect a particular manufacturer but do not restore exclusivity to Calcijex.
What are the investment scenarios for Calcijex?
Base case: commodity generic
Calcitriol injection remains available from multiple suppliers. Pricing is competitive, volume is stable or modestly declining, and margins reflect standard sterile-injectable economics.
Upside case: supply-constrained market
One or more manufacturers experience production interruptions. A reliable supplier gains share, improves utilization and obtains temporary price support. This scenario benefits an operator with approved capacity and strong quality performance.
Downside case: therapeutic substitution
Dialysis protocols shift toward alternative vitamin D analogs or calcimimetics. Calcitriol injection volume declines, and price competition intensifies as suppliers compete for a smaller market.
Strategic-acquisition case
A generic manufacturer acquires or licenses the product to use existing sterile capacity, expand its dialysis portfolio or strengthen hospital contracting. The value derives from portfolio synergies rather than Calcijex exclusivity.
What geographic markets are relevant to Calcijex?
The United States is the most important market for Orange Book and ANDA analysis. Other jurisdictions may regulate calcitriol injection through national marketing authorizations, hospital tenders or generic-registration systems.
Geographic value depends on:
- Local dialysis prevalence
- Public reimbursement
- Hospital tender structures
- Generic approval requirements
- Sterile-manufacturing standards
- Import dependence
- Availability of oral and injectable alternatives
A U.S. approval does not establish protection or market access in Europe, Japan, Canada or emerging markets. Each jurisdiction requires separate regulatory and commercial analysis.
Key Takeaways
- Calcijex is an injectable calcitriol product for hypocalcemia and secondary hyperparathyroidism associated with chronic renal dialysis.
- Its original patents and exclusivity have expired.
- No material active Orange Book patent estate blocks generic calcitriol injection.
- Paragraph IV litigation and branded-generic settlement risk are not major market factors.
- The product is not a biologic and has no biosimilar pathway.
- Generic competition, dialysis-provider purchasing and therapeutic substitution determine pricing.
- Sterile manufacturing, quality compliance and reliable supply are the main barriers to entry.
- Standalone Calcijex revenue is not a meaningful public-company financial disclosure category.
- The best investment case is a generic injectable platform or renal-care portfolio, not ownership of Calcijex as a protected branded asset.
FAQs About Calcijex Patent and Investment Risk
Is Calcijex still commercially protected by patents?
No. Calcijex is a mature, off-patent product with no material current patent protection blocking generic competition.
Can a generic company launch calcitriol injection without a Paragraph IV challenge?
Yes. Where no relevant unexpired listed patent blocks approval, an applicant can pursue the applicable ANDA certification pathway without relying on a Paragraph IV litigation strategy.
Is Calcijex a biologic requiring biosimilar approval?
No. Calcijex contains calcitriol, a small-molecule active ingredient. Generic approval, not biosimilar approval, governs competition.
What is the main manufacturing risk for calcitriol injection?
The main risk is sterile injectable production, including aseptic processing, low-dose uniformity, stability, particulate control, container-closure integrity and FDA inspection compliance.
Does Calcijex have stronger economics than oral calcitriol?
Injectable calcitriol can command different pricing and may be required in specific dialysis settings, but it also carries higher manufacturing and quality costs. Its economics depend on supply reliability, contracts and therapeutic substitution rather than patent-based pricing power.
References
- U.S. Food and Drug Administration. (n.d.). Calcijex (calcitriol injection) prescribing information.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Calcijex, NDA 018874.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Kidney Disease: Improving Global Outcomes. (2017). KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder. Kidney International Supplements, 7(1), 1-59.
- U.S. Centers for Medicare & Medicaid Services. (2024). End-stage renal disease prospective payment system.
